QPPV.COM KNOWLEDGE ASSESSMENT

Equine Anti-Thymocyte Globulin: Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Equine Anti-Thymocyte Globulin: Polyclonal T-Cell Immunosuppression and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the relationship between skin testing and anaphylaxis risk before equine ATG treatment?

A negative skin test guarantees that anaphylaxis cannot occur Skin testing can identify patients at increased risk but does not eliminate the possibility of a severe reaction Skin testing is used to confirm that the product is rabbit-derived Skin testing replaces the need for monitored intravenous administration

Question 2 of 10 Why is prior exposure to equine proteins or ATG particularly relevant when assessing a new immune reaction?

It establishes causality without the need for clinical details It may indicate prior sensitisation and can alter the risk or presentation on re-exposure It proves that the current product was manufactured incorrectly It eliminates the possibility of cytokine-release syndrome

Question 3 of 10 Why are serial platelet, neutrophil and lymphocyte measurements generally more informative than a single post-treatment result?

Serial data show baseline status, trajectory, timing and recovery, helping separate treatment effects from pre-existing or competing causes A single result is always analytically invalid Serial measurements prove causality regardless of clinical context Only serial measurements can identify the product's lot number

Question 4 of 10 Why should serum sickness not be recorded merely as an unspecified immediate allergy?

The distinction is irrelevant because all immune reactions have the same latency Broad coding can obscure the delayed timing and clinical constellation needed for signal detection and case assessment Serum sickness is not an immune-mediated condition Immediate allergy coding is required for every reaction to a biological medicine

Question 5 of 10 Which statement best captures the central pharmacovigilance implication of equine ATG's mechanism?

The safety profile can be understood solely by monitoring one receptor-mediated toxicity The assessment must integrate immediate immune reactions, delayed immune disease, infection, cytopenias, organ function and treatment context Only allergic reactions are plausibly related to the product Broad immunosuppression makes clinical chronology unnecessary

Question 6 of 10 A case report labels fever and hypotension as cytokine-release syndrome but contains no cultures, inflammatory assessment or discussion of infection. What is the main pharmacovigilance concern?

The report may have prematurely assigned a syndrome and missed an important competing diagnosis The case is automatically invalid because CRS cannot cause fever The absence of cultures proves that anaphylaxis occurred Diagnostic work-up is unnecessary when hypotension is present

Question 7 of 10 An infection case after equine ATG omits the patient's other immunosuppressive medicines. What is the main consequence?

The case becomes impossible to enter into a safety database Assessment of total immunosuppressive burden and attribution to equine ATG becomes less reliable The infection must be classified as unrelated to treatment The omission affects only product-quality investigations

Question 8 of 10 Which report would be most useful for assessing a suspected serum sickness case after equine ATG?

A report stating only 'allergy occurred' with no onset date or clinical findings A report documenting course day, prior exposure, onset after treatment, fever, rash, arthralgia, lymphadenopathy, treatment and outcome A report containing only the product lot number A report describing only the patient's baseline platelet count

Question 9 of 10 Which inspection or governance control most directly addresses the risk of confusing equine and rabbit ATG in pharmacovigilance data?

Using a product dictionary that records the full biological identity of each ATG preparation Removing all manufacturer and product information from case reports Coding every ATG report under one undifferentiated generic term Recording only the therapeutic indication

Question 10 of 10 Which information is most important when evaluating abnormal renal or hepatic tests in a transplant recipient treated with equine ATG?

Baseline values and competing causes such as graft dysfunction, rejection, infection and concomitant nephrotoxic medicines Only the maximum laboratory value after treatment Only whether the patient had a history of allergy The number of nurses present during the infusion

Equine Anti-Thymocyte Globulin: Pharmacovigilance Knowledge Assessment

Cookie Settings